Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post sales of $5.77 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.18 million and the highest estimate coming in at $9.20 million. BioCryst Pharmaceuticals reported sales of $8.98 million in the same quarter last year, which indicates a negative year over year growth rate of 35.7%. The business is scheduled to report its next earnings report on Monday, February 26th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $5.77 million for the current financial year, with estimates ranging from $18.82 million to $30.50 million. For the next fiscal year, analysts anticipate that the firm will report sales of $26.45 million per share, with estimates ranging from $16.75 million to $35.19 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The firm had revenue of $8.76 million during the quarter, compared to analyst estimates of $5.05 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year.
Several equities research analysts have recently commented on the stock. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average target price of $9.13.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at $4.70 on Wednesday. BioCryst Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.
In related news, CMO William P. Sheridan sold 64,310 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Fred E. Cohen sold 54,250 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the sale, the director now directly owns 173,660 shares of the company’s stock, valued at $941,237.20. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $23,762,000. Alyeska Investment Group L.P. purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $2,358,000. Allianz Asset Management GmbH increased its holdings in BioCryst Pharmaceuticals by 35.5% in the 3rd quarter. Allianz Asset Management GmbH now owns 159,364 shares of the biotechnology company’s stock worth $835,000 after acquiring an additional 41,727 shares in the last quarter. VHCP Management II LLC increased its holdings in BioCryst Pharmaceuticals by 27.9% in the 3rd quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after acquiring an additional 690,290 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock worth $1,678,000 after acquiring an additional 12,267 shares in the last quarter. 84.69% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/06/biocryst-pharmaceuticals-inc-bcrx-expected-to-post-quarterly-sales-of-5-77-million.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.